Seattle stem cell startup Curi Bio raises $6M
GeekWire
MARCH 19, 2021
Curi Bio Chief Business Officer Elliot Fisher and CEO Michael Cho. (Curi Bio Photos). New funding: Curi Bio raised $6 million to further develop its human stem cell-based platforms for drug discovery. Dynamk Capital led the Series A round. Company background: The Seattle startup, previously known as NanoSurface Biomedical, aims to provide drug developers with human-relevant cells, systems, and data to speed up the drug discovery process in the cardiac, skeletal muscle, and neuromuscular fields.
Let's personalize your content